AZM 475271

Key Product Details

Product Description

AZM 475271 is a src tyrosine kinase inhibitor. Reduces tumor size, vascularity and metastasis, and increases apoptosis in human pancreatic cells grown in nude mice. Also exhibits antiangiogenic activity in vitro and in vivo. Sensitizes tumor cells to the cytotoxic effects of gemcitabine (Cat. No. 3259).

Licensing Information

Sold with the permission of AstraZeneca UK Ltd.

Product Specifications for AZM 475271

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AZM 475271

The following data is based on the product molecular weight 442.94.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.26 mL	11.29 mL	22.58 mL
5 mM	0.45 mL	2.26 mL	4.52 mL
10 mM	0.23 mL	1.13 mL	2.26 mL
50 mM	0.05 mL	0.23 mL	0.45 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 14 publications citing the usage of this product.

• Summy AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol.Cancer Ther. 2005 PMID: 16373705
• Yezhelyev Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin.Cancer Res. 2004 PMID: 15585638

Product Documents for AZM 475271